Sidibé, Bakary
Agniwo, Privat
Diakité, Assitan
Savassi, Boris Agossou Eyaton-olodji Sègnito
Doumbo, Safiatou Niaré
Akplogan, Ahristode
Guindo, Hassim
Ibikounlé, Moudachirou
Dembélé, Laurent
Djimde, Abdoulaye
Boissier, Jérôme
Dabo, Abdoulaye
Article History
Received: 16 April 2024
Accepted: 2 August 2024
First Online: 29 August 2024
Declarations
:
: The study protocol was approved by the Institutional Ethics Committee of the Faculty of Medicine and Odontology of Bamako under reference number 2018/71/CE/FMPOS. Prior to conducting the study, authorities (school staff and community leaders) were consulted to gain full access to communities and grassroots schools. School authorities, teachers, parents/guardians and children were informed of the objectives, procedures and potential risks and benefits of the study. Verbal informed consent/assent was obtained from the children's parents or legal guardians and from the children respectively. Participation in the study was made voluntary thus children could refuse to participate without any consequences. After sampling, children with <i>Schistosoma</i> infection were treated with praziquantel in accordance with the WHO guidelines (40 mg/kg). For data protection purposes, an identification number was assigned to each participant.
: Not applicable.
: The authors declare that they have no competing of interest. Ethical approval Ethical permission was obtained from the Ethic Committee of the” Faculté de Médecin et d’Odontostomatologie FMOS de Bamako, Mali”.